{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:58Z","timestamp":1791644338505,"version":"4.3.4"},"reference-count":193,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025JJ80089"],"award-info":[{"award-number":["2025JJ80089"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["23B0383"],"award-info":[{"award-number":["23B0383"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Excellent Youth Fund Support Project of the Research Project of the Education Bureau of Hunan Province","award":["2025JJ80089"],"award-info":[{"award-number":["2025JJ80089"]}]},{"name":"Excellent Youth Fund Support Project of the Research Project of the Education Bureau of Hunan Province","award":["23B0383"],"award-info":[{"award-number":["23B0383"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) represents a critical hepatic manifestation within the broader spectrum of metabolic syndrome. The pathogenesis of MASH is characterized by disruptions in lipid metabolism, inflammation, and fibrosis. Bile acids and their receptors are integral to the progression of MASH, primarily through their regulatory influence on the metabolic networks of the gut\u2013liver axis. This review offers a comprehensive and systematic examination of the molecular mechanisms underlying bile acid biosynthesis, metabolic dysregulation, and receptor signaling anomalies in MASH. Furthermore, it explores the translational potential of these insights into clinical therapies. Bile acids and their receptors emerge as pivotal therapeutic targets for MASH. Future research should focus on an in-depth analysis of dynamic regulatory mechanisms and the optimization of multi-target combination therapies, thereby paving the way for significant clinical advancements.<\/jats:p>","DOI":"10.3390\/molecules30153066","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:00:42Z","timestamp":1753196442000},"page":"3066","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multifaceted Interactions Between Bile Acids, Their Receptors, and MASH: From Molecular Mechanisms to Clinical Therapeutics"],"prefix":"10.3390","volume":"30","author":[{"given":"Xuan","family":"Tang","sequence":"first","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xia","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulian","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4609-501X","authenticated-orcid":false,"given":"Yamei","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and Opportunities in NASH Drug Development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic Inhibition of Lipogenesis for the Treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-Regulated Lipid Metabolism: Convergent Physiology\u2014Divergent Pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab. Clin. Exp."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101222","DOI":"10.1016\/j.jhepr.2024.101222","article-title":"Sex Differences in Murine MASH Induced by a Fructose-Palmitate-Cholesterol-Enriched Diet","volume":"7","author":"Arivazhagan","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the Global Public Health Agenda for NAFLD: A Consensus Statement","volume":"19","author":"Lazarus","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","article-title":"A Researcher\u2019s Guide to Preclinical Mouse NASH Models","volume":"4","author":"Gallage","year":"2022","journal-title":"Nat. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.redox.2018.01.009","article-title":"Role of Gut Microbiota and Oxidative Stress in the Progression of Non-Alcoholic Fatty Liver Disease to Hepatocarcinoma: Current and Innovative Therapeutic Approaches","volume":"15","author":"Borrelli","year":"2018","journal-title":"Redox Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.pathol.2022.01.009","article-title":"Prevalence and Clinical Significance of Portal Inflammation, Portal Plasma Cells, Interface Hepatitis and Biliary Injury in Liver Biopsies from Patients with Non-Alcoholic Steatohepatitis","volume":"54","author":"Dhingra","year":"2022","journal-title":"Pathology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/oby.23250","article-title":"Preparing for the NASH Epidemic: A Call to Action","volume":"29","author":"Kanwal","year":"2021","journal-title":"Obesity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 Reverses MASH through Coordinated Actions on the CNS and Liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1038\/s41467-024-51571-8","article-title":"RNA Nanotherapeutics with Fibrosis Overexpression and Retention for MASH Treatment","volume":"15","author":"Shan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jare.2023.06.009","article-title":"Bile Acid and Nonalcoholic Steatohepatitis: Molecular Insights and Therapeutic Targets","volume":"59","author":"Cheng","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Suvarna, R., Shetty, S., and Pappachan, J.M. (2024). Efficacy and Safety of Resmetirom, a Selective Thyroid Hormone Receptor-\u03b2 Agonist, in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-70242-8"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2021.03.017","article-title":"Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"20","author":"Jirapinyo","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"108238","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile Acid Metabolism and Signaling, the Microbiota, and Metabolic Disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/19490976.2019.1674124","article-title":"Diversification of Host Bile Acids by Members of the Gut Microbiota","volume":"11","author":"Winston","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile Acid Signaling in Metabolic Disease and Drug Therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2020.07.034","article-title":"Bile Acid Transporter-Mediated Oral Drug Delivery","volume":"327","author":"Deng","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2014.12.006","article-title":"Thyroid-Stimulating Hormone Regulates Hepatic Bile Acid Homeostasis via SREBP-2\/HNF-4\u03b1\/CYP7A1 Axis","volume":"62","author":"Song","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.stem.2022.08.008","article-title":"Hepatic Cytochrome P450 8B1 and Cholic Acid Potentiate Intestinal Epithelial Injury in Colitis by Suppressing Intestinal Stem Cell Renewal","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cmet.2015.01.007","article-title":"MAFG Is a Transcriptional Repressor of Bile Acid Synthesis and Metabolism","volume":"21","author":"Tarling","year":"2015","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1093\/nar\/29.19.4035","article-title":"Suppression of Sterol 12\u03b1-Hydroxylase Transcription by the Short Heterodimer Partner: Insights into the Repression Mechanism","volume":"29","author":"Gil","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-1877-9656","article-title":"Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update","volume":"42","author":"Chew","year":"2022","journal-title":"Semin. Liver Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.plipres.2022.101210","article-title":"Bile Acids and Their Receptors in Regulation of Gut Health and Diseases","volume":"89","author":"Lin","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13238-020-00804-9","article-title":"Targeting the Alternative Bile Acid Synthetic Pathway for Metabolic Diseases","volume":"12","author":"Jia","year":"2020","journal-title":"Protein Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/hep4.2041","article-title":"Bile Acid Conjugation Deficiency Causes Hypercholanemia, Hyperphagia, Islet Dysfunction, and Gut Dysbiosis in Mice","volume":"6","author":"Alrehaili","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00018-017-2472-6","article-title":"ABCB4 Missense Mutations D243A, K435T, G535D, I490T, R545C, and S978P Significantly Impair the Lipid Floppase and Likely Predispose to Secondary Pathologies in the Human Population","volume":"74","author":"Andress","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42255-024-01177-7","article-title":"Intestinal TM6SF2 Protects against Metabolic Dysfunction-Associated Steatohepatitis through the Gut\u2013Liver Axis","volume":"7","author":"Zhang","year":"2025","journal-title":"Nat. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut Symbionts Alleviate MASH through a Secondary Bile Acid Biosynthetic Pathway","volume":"187","author":"Nie","year":"2024","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-024-00896-2","article-title":"Another Renaissance for Bile Acid Gastrointestinal Microbiology","volume":"21","author":"Ridlon","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.ejps.2022.106335","article-title":"Novel Nitroxide-Bile Acid Conjugates Inform Substrate Requirements for Human Bile Acid Transporters","volume":"180","author":"Metry","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial Bile Acid Metabolites Modulate Gut ROR\u03b3+ Regulatory T Cell Homeostasis","volume":"577","author":"Song","year":"2019","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Ciaula, A., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H.H., Wang, D.Q.-H., and Portincasa, P. (2022). Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Nutrients, 14.","DOI":"10.3390\/nu14234950"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101392","DOI":"10.1016\/j.jcmgh.2024.101392","article-title":"Quantifying Forms and Functions of Enterohepatic Bile Acid Pools in Mice","volume":"18","author":"Sudo","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cebi, M., and Yilmaz, Y. (2025). Epithelial Barrier Hypothesis in the Context of Nutrition, Microbial Dysbiosis, and Immune Dysregulation in Metabolic Dysfunction-Associated Steatotic Liver. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1575770"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Long, C., Zhou, X., Xia, F., and Zhou, B. (2024). Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations. Biology, 13.","DOI":"10.3390\/biology13040243"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2508951","DOI":"10.1080\/19490976.2025.2508951","article-title":"Meta-Analysis of Shotgun Sequencing of Gut Microbiota in Obese Children with MASLD or MASH","volume":"17","author":"Kavallar","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"102090","DOI":"10.1016\/j.molmet.2024.102090","article-title":"Intrahepatic Levels of Microbiome-Derived Hippurate Associates with Improved Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"92","author":"Deslande","year":"2025","journal-title":"Mol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2025.02.033","article-title":"Integrative Metabolism in MASLD and MASH: Pathophysiology and Emerging Mechanisms","volume":"83","author":"Steinberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile Acids and Their Receptors in Metabolic Disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bcp.2013.07.022","article-title":"Differential Activation of the Human Farnesoid X Receptor Depends on the Pattern of Expressed Isoforms and the Bile Acid Pool Composition","volume":"86","author":"Vaquero","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.42.111901.111051","article-title":"Regulation of CYP3A Gene Transcription by the Pregnane X Receptor","volume":"42","author":"Goodwin","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.apsb.2021.12.011","article-title":"Bile Acid Coordinates Microbiota Homeostasis and Systemic Immunometabolism in Cardiometabolic Diseases","volume":"12","author":"Guan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","article-title":"Bile Acid-Activated Receptors in the Treatment of Dyslipidemia and Related Disorders","volume":"49","author":"Fiorucci","year":"2010","journal-title":"Prog. Lipid Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Qi, Y., Duan, G., Wei, D., Zhao, C., and Ma, Y. (2022). The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?. Molecules, 27.","DOI":"10.3390\/molecules27165292"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","article-title":"Bile Acids in Glucose Metabolism and Insulin Signalling\u2014Mechanisms and Research Needs","volume":"15","author":"Ahmad","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2021.12.006","article-title":"Crosstalk between Bile Acid-Activated Receptors and Microbiome in Entero-Hepatic Inflammation","volume":"28","author":"Thibaut","year":"2022","journal-title":"Trends Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lee, S.M., Ahn, Y.M., Park, S.-H., Shin, S., and Jung, J. (2023). Reshaping the Gut Microbiome and Bile Acid Composition by Gyejibongnyeong-Hwan Ameliorates Western Diet-Induced Dyslipidemia. Biomed. Pharmacother., 163.","DOI":"10.1016\/j.biopha.2023.114826"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Joseph, S.C., Eugin Simon, S., Bohm, M.S., Kim, M., Pye, M.E., Simmons, B.W., Graves, D.G., Thomas-Gooch, S.M., Tanveer, U.A., and Holt, J.R. (2024). FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden. Cancers, 16.","DOI":"10.20944\/preprints202401.1876.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep4.1256","article-title":"FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice","volume":"2","author":"Calenda","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/liv.14052","article-title":"Bile Acids Increase Steroidogenesis in Cholemic Mice and Induce Cortisol Secretion in Adrenocortical H295R Cells via S1 PR 2, ERK and SF -1","volume":"39","author":"Liu","year":"2019","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"\u0160arenac, T.M., and Mikov, M. (2018). Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00939"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted Disruption of the Nuclear Receptor FXR\/BAR Impairs Bile Acid and Lipid Homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1172\/JCI94029","article-title":"RNA-Binding Protein ZFP36L1 Maintains Posttranscriptional Regulation of Bile Acid Metabolism","volume":"127","author":"Tarling","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1194\/jlr.M069807","article-title":"Cholesterol 7\u03b1-Hydroxylase Protects the Liver from Inflammation and Fibrosis by Maintaining Cholesterol Homeostasis","volume":"57","author":"Liu","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-Protein-Coupled Bile Acid Receptor, Gpbar1 (TGR5), Negatively Regulates Hepatic Inflammatory Response through Antagonizing Nuclear Factor Kappa Light-Chain Enhancer of Activated B Cells (NF-\u03baB) in Mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2308771","DOI":"10.1002\/advs.202308771","article-title":"Pregnane X Receptor Activation in Liver Macrophages Protects against Endotoxin-Induced Liver Injury","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","article-title":"Nuclear Receptor FXR, Bile Acids and Liver Damage: Introducing the Progressive Familial Intrahepatic Cholestasis with FXR Mutations","volume":"1864","author":"Cariello","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_61","first-page":"247","article-title":"Blocking Sodium-Taurocholate Cotransporting Polypeptide Stimulates Biliary Cholesterol and Phospholipid Secretion in Mice","volume":"71","author":"Slijepcevic","year":"2019","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tem.2017.02.001","article-title":"SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis","volume":"28","author":"Linton","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_63","first-page":"1927","article-title":"Activation of FXR by Obeticholic Acid Induces Hepatic Gene Expression of SR-BI through a Novel Mechanism of Transcriptional Synergy with the Nuclear Receptor LXR","volume":"43","author":"Dong","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation Inhibitors Synergize with FXR Agonists in Combating Liver Fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e03150-24","DOI":"10.1128\/spectrum.03150-24","article-title":"Activation of Gut FXR Improves the Metabolism of Bile Acids, Intestinal Barrier, and Microbiota under Cholestatic Condition Caused by GCDCA in Mice","volume":"13","author":"Xie","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical Relevance of the Bile Acid Receptor TGR5 in Metabolism","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic Acid Species Improve Glucose Homeostasis through a Distinct TGR5 and FXR Signaling Mechanism","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41420-022-01162-7","article-title":"RING-Finger E3 Ligases Regulatory Network in PI3K\/AKT-Mediated Glucose Metabolism","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Liu, Y., Qiu, Y., Chen, Q., Han, X., Cai, M., and Hao, L. (2021). Puerarin Suppresses the Hepatic Gluconeogenesis via Activation of PI3K\/Akt Signaling Pathway in Diabetic Rats and HepG2 Cells. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111325"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Vettorazzi, J.F., Kurauti, M.A., Soares, G.M., Borck, P.C., Ferreira, S.M., Branco, R.C.S., Michelone, L.D.S.L., Boschero, A.C., Junior, J.M.C., and Carneiro, E.M. (2017). Bile Acid TUDCA Improves Insulin Clearance by Increasing the Expression of Insulin-Degrading Enzyme in the Liver of Obese Mice. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-13974-0"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2300927","DOI":"10.1002\/mnfr.202300927","article-title":"Postbiotics Prepared Using Lactobacillus Reuteri Ameliorates Ethanol-Induced Liver Injury by Regulating the FXR\/SHP\/SREBP-1c Axis","volume":"68","author":"Liu","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile Acids Induce Energy Expenditure by Promoting Intracellular Thyroid Hormone Activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Cao, Y., Shu, X., Li, M., Yu, S., Li, C., Ji, G., and Zhang, L. (2022). Jiangzhi Granule Attenuates Non-Alcoholic Steatohepatitis through Modulating Bile Acid in Mice Fed High-Fat Vitamin D Deficiency Diet. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112825"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.toxlet.2017.03.028","article-title":"Pregnane X Receptor Regulates the AhR\/Cyp1A1 Pathway and Protects Liver Cells from Benzo-[\u03b1]-Pyrene-Induced DNA Damage","volume":"275","author":"Cui","year":"2017","journal-title":"Toxicol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"114344","DOI":"10.1016\/j.jep.2021.114344","article-title":"Saikosaponins and the Deglycosylated Metabolites Exert Liver Meridian Guiding Effect through PXR\/CYP3A4 Inhibition","volume":"279","author":"Liu","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"106222","DOI":"10.1016\/j.aquatox.2022.106222","article-title":"Response of the Sirtuin\/PXR Signaling Pathway in Mugilogobius Chulae Exposed to Environmentally Relevant Concentration Paracetamol","volume":"249","author":"Meinan","year":"2022","journal-title":"Aquat. Toxicol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.biopha.2019.01.015","article-title":"Activation of Constitutive Androstane Receptor Inhibits Intestinal CFTR-Mediated Chloride Transport","volume":"111","author":"Kittayaruksakul","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","article-title":"CAR and PXR Agonists Stimulate Hepatic Bile Acid and Bilirubin Detoxification and Elimination Pathways in Mice\u2020","volume":"42","author":"Wagner","year":"2005","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Tang, Y., Fan, Y., Wang, Y., Wang, D., Huang, Q., Chen, T., Cao, X., Wen, C., Shen, X., and Li, J. (2024). A Current Understanding of FXR in NAFLD: The Multifaceted Regulatory Role of FXR and Novel Lead Discovery for Drug Development. Biomed. Pharmacother., 175.","DOI":"10.1016\/j.biopha.2024.116658"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.jhepr.2024.101148","article-title":"A Gut Microbiota-Independent Mechanism Shapes the Bile Acid Pool in Mice with MASH","volume":"6","author":"Gillard","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic Acid Alleviates Non-Alcoholic Fatty Liver Disease through Modulating the Gut-Liver Axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"155919","DOI":"10.1016\/j.phymed.2024.155919","article-title":"Yellow Tea Polysaccharides Protect against Non-Alcoholic Fatty Liver Disease via Regulation of Gut Microbiota and Bile Acid Metabolism in Mice","volume":"133","author":"Huang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcmgh.2016.10.002","article-title":"Targeting the Enterohepatic Bile Acid Signaling Induces Hepatic Autophagy via a CYP7A1\u2013AKT\u2013mTOR Axis in Mice","volume":"3","author":"Wang","year":"2017","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1042\/CS20201363","article-title":"Arrb2 Causes Hepatic Lipid Metabolism Disorder via AMPK Pathway Based on Metabolomics in Alcoholic Fatty Liver","volume":"135","author":"Sun","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","article-title":"Hepatic FXR-FGF4 Is Required for Bile Acid Homeostasis via an FGFR4-LRH-1 Signal Node under Cholestatic Stress","volume":"37","author":"Song","year":"2025","journal-title":"Cell Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease","volume":"152","author":"Tailleux","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The Protective Effect and Mechanism of the FXR Agonist Obeticholic Acid via Targeting Gut Microbiota in Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jmedchem.5b00342","article-title":"Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases","volume":"59","author":"Xu","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed Hepatic Bile Acid Signalling despite Elevated Production of Primary and Secondary Bile Acids in NAFLD","volume":"67","author":"Jiao","year":"2017","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"116945","DOI":"10.1016\/j.jep.2023.116945","article-title":"Enhancing NKT Cell-Mediated Immunity against Hepatocellular Carcinoma: Role of XYXD in Promoting Primary Bile Acid Synthesis and Improving Gut Microbiota","volume":"318","author":"Deng","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00011-024-01884-7","article-title":"Impacts of Liver Macrophages, Gut Microbiota, and Bile Acid Metabolism on the Differences in iHFC Diet-Induced MASH Progression between TSNO and TSOD Mice","volume":"73","author":"Igarashi","year":"2024","journal-title":"Inflamm. Res."},{"key":"ref_92","first-page":"1097","article-title":"Metabolic Reprogramming of Immune Cells in MASH","volume":"10","author":"Ma","year":"2025","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2020.09.004","article-title":"Precise Delivery of Obeticholic Acid via Nanoapproach for Triggering Natural Killer T Cell-Mediated Liver Cancer Immunotherapy","volume":"10","author":"Ji","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ren, Z.-L., Li, C.-X., Ma, C.-Y., Chen, D., Chen, J.-H., Xu, W.-X., Chen, C.-A., Cheng, F.-F., and Wang, X.-Q. (2022). Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113045"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hep.32787","article-title":"Combinatorial Targeting of G-protein-coupled Bile Acid Receptor 1 and Cysteinyl Leukotriene Receptor 1 Reveals a Mechanistic Role for Bile Acids and Leukotrienes in Drug-induced Liver Injury","volume":"78","author":"Biagioli","year":"2022","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Endo-Umeda, K., and Makishima, M. (2019). Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205045"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Xie, G., Jiang, R., Wang, X., Liu, P., Zhao, A., Wu, Y., Huang, F., Liu, Z., Rajani, C., and Zheng, X. (2021). Conjugated Secondary 12\u03b1-Hydroxylated Bile Acids Promote Liver Fibrogenesis. eBioMedicine, 66.","DOI":"10.1016\/j.ebiom.2021.103290"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"He, B., Jiang, J., Shi, Z., Wu, L., Yan, J., Chen, Z., Luo, M., Cui, D., Xu, S., and Yan, M. (2021). Pure Total Flavonoids from Citrus Attenuate Non-Alcoholic Steatohepatitis via Regulating the Gut Microbiota and Bile Acid Metabolism in Mice. Biomed. Pharmacother., 135.","DOI":"10.1016\/j.biopha.2020.111183"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"20194","DOI":"10.1021\/acs.jafc.4c04630","article-title":"Tauroursodeoxycholic Acid Improves Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Bile Acid Metabolism","volume":"72","author":"Wang","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"131760","DOI":"10.1016\/j.jhazmat.2023.131760","article-title":"Multi-Omics Reveals 2-Bromo-4,6-Dinitroaniline (BDNA)-Induced Hepatotoxicity and the Role of the Gut-Liver Axis in Rats","volume":"457","author":"Deng","year":"2023","journal-title":"J. Hazard. Mater."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2304408","DOI":"10.1002\/advs.202304408","article-title":"Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid","volume":"11","author":"Wu","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Fu, K., Ma, C., Wang, C., Zhou, H., Gong, L., Zhang, Y., and Li, Y. (2022). Forsythiaside A Alleviated Carbon Tetrachloride-Induced Liver Fibrosis by Modulating Gut Microbiota Composition to Increase Short-Chain Fatty Acids and Restoring Bile Acids Metabolism Disorder. Biomed. Pharmacother., 151.","DOI":"10.1016\/j.biopha.2022.113185"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1039\/D1FO04241F","article-title":"Antarctic Krill Peptide Alleviates Liver Fibrosis via Downregulating the Secondary Bile Acid Mediated NLRP3 Signaling Pathway","volume":"13","author":"Yue","year":"2022","journal-title":"Food Funct."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Wang, N., Lu, S., Xiong, J., Yuan, Y., Liu, J., and Chen, S. (2023). Targeting Hepatic Ceruloplasmin Mitigates Nonalcoholic Steatohepatitis by Modulating Bile Acid Metabolism. J. Mol. Cell Biol., 15.","DOI":"10.1093\/jmcb\/mjad060"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.bbadis.2017.08.021","article-title":"Bile Acid Receptors in the Biliary Tree: TGR5 in Physiology and Disease","volume":"1864","author":"Deutschmann","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 Inflammasome Blockade Reduces Liver Inflammation and Fibrosis in Experimental NASH in Mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"117250","DOI":"10.1016\/j.ejmech.2025.117250","article-title":"Design, Synthesis, and Anti-Liver Fibrosis Activity of Novel Non-Steroidal Vitamin D Receptor Agonists Based on Open-Ring Steroid Scaffold","volume":"286","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/hep.23721","article-title":"Transgenic Expression of Cholesterol 7\u03b1-hydroxylase in the Liver Prevents High-fat Diet\u2013Induced Obesity and Insulin Resistance in Mice\u2020","volume":"52","author":"Li","year":"2010","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X Receptor Is Essential for Normal Glucose Homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1172\/JCI88893","article-title":"Nutrient-Sensing Nuclear Receptors PPAR\u03b1 and FXR Control Liver Energy Balance","volume":"127","author":"Preidis","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2017.01.006","article-title":"Bile Acids and Their Receptors","volume":"56","author":"Martinot","year":"2017","journal-title":"Mol. Aspects Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2390136","DOI":"10.1080\/19490976.2024.2390136","article-title":"Quercetin Activates Energy Expenditure to Combat Metabolic Syndrome through Modulating Gut Microbiota-Bile Acids Crosstalk in Mice","volume":"16","author":"Zhu","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"154982","DOI":"10.1016\/j.phymed.2023.154982","article-title":"Red Ginseng Extracts Ameliorate High-Fat Diet-Induced Obesity and Insulin Resistance by Activating the Intestinal TGR5-Mediated Bile Acids Signaling Pathway","volume":"119","author":"Li","year":"2023","journal-title":"Phytomedicine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1074\/jbc.M115.699504","article-title":"Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet \u03b1 Cells to Promote Glucose Homeostasis","volume":"291","author":"Kumar","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The Physiology of Glucagon-like Peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine Farnesoid X Receptor Agonist and the Gut Microbiota Activate G-protein Bile Acid Receptor-1 Signaling to Improve Metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in Bile Salt Based Therapies: A Critical Overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kakiyama, G., Rodriguez-Agudo, D., and Pandak, W.M. (2023). Mitochondrial Cholesterol Metabolites in a Bile Acid Synthetic Pathway Drive Nonalcoholic Fatty Liver Disease: A Revised \u201cTwo-Hit\u201d Hypothesis. Cells, 12.","DOI":"10.3390\/cells12101434"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/s41401-024-01303-x","article-title":"A New Mechanism of Thyroid Hormone Receptor \u03b2 Agonists Ameliorating Nonalcoholic Steatohepatitis by Inhibiting Intestinal Lipid Absorption via Remodeling Bile Acid Profiles","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","article-title":"Neuroprotective Strategies for Retinal Disease","volume":"65","author":"Pardue","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1050-1738(00)00043-8","article-title":"FXR, a Bile Acid Receptor and Biological Sensor","volume":"10","author":"Tu","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Lee, S.M., Jun, D.W., Yoon, E.L., Oh, J.H., Roh, Y.J., Lee, E.J., Shin, J.-H., Nam, Y.-D., and Kim, H.S. (2023). Discovery Biomarker to Optimize Obeticholic Acid Treatment for Non-Alcoholic Fatty Liver Disease. Biol. Direct, 18.","DOI":"10.1186\/s13062-023-00407-4"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Kouno, T., Liu, X., Zhao, H., Kisseleva, T., Cable, E.E., and Schnabl, B. (2022). Selective PPAR\u03b4 Agonist Seladelpar Suppresses Bile Acid Synthesis by Reducing Hepatocyte CYP7A1 via the Fibroblast Growth Factor 21 Signaling Pathway. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.102056"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1073\/pnas.0712038105","article-title":"Symbiotic Gut Microbes Modulate Human Metabolic Phenotypes","volume":"105","author":"Li","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"155942","DOI":"10.1016\/j.metabol.2024.155942","article-title":"The Mitochondrial TSPO Ligand Atriol Mitigates Metabolic-Associated Steatohepatitis by Downregulating CXCL1","volume":"159","author":"Li","year":"2024","journal-title":"Metab. Clin. Exp."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"100527","DOI":"10.1016\/j.jlr.2024.100527","article-title":"Hepatic FOXA3 Overexpression Prevents Western Diet\u2013Induced Obesity and MASH through TGR5","volume":"65","author":"Gopoju","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.1021\/acs.jmedchem.0c01065","article-title":"Discovery and Optimization of Non-Bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X Receptor (FXR): Structures and Ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1142\/S0192415X24500137","article-title":"Natural Products in the Modulation of Farnesoid X Receptor Against Nonalcoholic Fatty Liver Disease","volume":"52","author":"Wang","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of Antibacterial Defense in the Small Intestine by the Nuclear Bile Acid Receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of Bile Acids in Metabolic Control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR Agonists for MASH Therapy: Lessons and Perspectives from Obeticholic Acid","volume":"44","author":"Wang","year":"2023","journal-title":"Med. Res. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/hep4.2099","article-title":"Glycine-\u03b2-muricholic Acid Antagonizes the Intestinal Farnesoid X Receptor\u2013Ceramide Axis and Ameliorates NASH in Mice","volume":"6","author":"Jiang","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and Challenges of Selective Farnesoid X Receptor Modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Zhang, L., Feng, F., Wang, X., Liang, H., Yao, X., and Liu, D. (2024). Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models. Pharmaceuticals, 17.","DOI":"10.3390\/ph17030369"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile Acid Metabolism and Signaling in Health and Disease: Molecular Mechanisms and Therapeutic Targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coph.2017.09.008","article-title":"Modulating Bile Acid Pathways and TGR5 Receptors for Treating Liver and GI Diseases","volume":"37","author":"Malhi","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Festa, C., De Marino, S., Carino, A., Sepe, V., Marchian\u00f2, S., Cipriani, S., Di Leva, F.S., Limongelli, V., Monti, M.C., and Capolupo, A. (2017). Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00162"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Zhou, T., Ismail, A., and Francis, H. (2023). Bile Acids in Autoimmune Liver Disease: Unveiling the Nexus of Inflammation, Inflammatory Cells, and Treatment Strategies. Cells, 12.","DOI":"10.3390\/cells12232725"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e031241","DOI":"10.1161\/JAHA.123.031241","article-title":"Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1\/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease","volume":"12","author":"Biagioli","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-14-0154","article-title":"MECHANISMS IN ENDOCRINOLOGY: Bile Acid Sequestrants in Type 2 Diabetes: Potential Effects on GLP1 Secretion","volume":"171","author":"Sonne","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","article-title":"INT-767 Improves Histopathological Features in a Diet-Induced Ob\/Ob Mouse Model of Biopsy-Confirmed Non-Alcoholic Steatohepatitis","volume":"24","author":"Roth","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.tips.2024.10.002","article-title":"Novel Antagonists Reveal the Mechanism of PXR Inhibition","volume":"45","author":"Kamaraj","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Xue, R., Su, L., Lai, S., Wang, Y., Zhao, D., Fan, J., Chen, W., Hylemon, P.B., and Zhou, H. (2021). Bile Acid Receptors and the Gut\u2013Liver Axis in Nonalcoholic Fatty Liver Disease. Cells, 10.","DOI":"10.3390\/cells10112806"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1021\/acs.nanolett.1c01360","article-title":"Manipulating Liver Bile Acid Signaling by Nanodelivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy","volume":"21","author":"Ji","year":"2021","journal-title":"Nano Lett."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile Acid Sequestration Reverses Liver Injury and Prevents Progression of Nonalcoholic Steatohepatitis in Western Diet\u2013Fed Mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2024.09.037","article-title":"Inhibition of ATGL Alleviates MASH via Impaired PPAR\u03b1 Signalling That Favours Hydrophilic Bile Acid Composition in Mice","volume":"82","author":"Dixon","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator\u2212Activated Receptor\u2212\u03b1 and \u2212\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","article-title":"The Therapeutic Landscape of Non-alcoholic Steatohepatitis","volume":"37","author":"Perazzo","year":"2016","journal-title":"Liver Int."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"14219","DOI":"10.3748\/wjg.v20.i39.14219","article-title":"Non-Alcoholic Fatty Liver Disease: What Has Changed in the Treatment since the Beginning?","volume":"20","author":"Baran","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.12543","article-title":"Systematic Review with Meta-Analysis: Non-Alcoholic Steatohepatitis\u2014A Case for Personalised Treatment Based on Pathogenic Targets","volume":"39","author":"Younossi","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development","volume":"71","author":"Mouries","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev-pharmtox-010617-052545","article-title":"Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies","volume":"58","author":"Wattacheril","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"G412","DOI":"10.1152\/ajpgi.00300.2018","article-title":"Intestinal TGR5 Agonism Improves Hepatic Steatosis and Insulin Sensitivity in Western Diet-Fed Mice","volume":"316","author":"Finn","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Shi, Y., Su, W., Zhang, L., Shi, C., Zhou, J., Wang, P., Wang, H., Shi, X., Wei, S., and Wang, Q. (2021). TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.609060"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S2468-1253(23)00159-0","article-title":"NASH Drug Treatment Development: Challenges and Lessons","volume":"8","author":"Tilg","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/hep.31177","article-title":"New Drugs for NASH and HIV Infection: Great Expectations for a Great Need","volume":"71","author":"Guaraldi","year":"2020","journal-title":"Hepatology"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Zhang, M., Barroso, E., Ruart, M., Pe\u00f1a, L., Peyman, M., Aguilar-Recarte, D., Montori-Grau, M., Rada, P., Cugat, C., and Montironi, C. (2023). Elafibranor Upregulates the EMT-Inducer S100A4 via PPAR\u03b2\/\u03b4. Biomed. Pharmacother., 167.","DOI":"10.1016\/j.biopha.2023.115623"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/CM9.0000000000002156","article-title":"Bile Acids and Sphingolipids in Non-Alcoholic Fatty Liver Disease","volume":"135","author":"Jackson","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-med-051215-031109","article-title":"Nonalcoholic Steatohepatitis","volume":"68","author":"Suzuki","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel Therapeutic Targets for Cholestatic and Fatty Liver Disease","volume":"71","author":"Trauner","year":"2021","journal-title":"Gut"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An Intestinal Microbiota\u2013Farnesoid X Receptor Axis Modulates Metabolic Disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A Structurally Optimized FXR Agonist, MET409, Reduced Liver Fat Content over 12 Weeks in Patients with Non-Alcoholic Steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Guo, C., Chen, W.-D., and Wang, Y.-D. (2016). TGR5, Not Only a Metabolic Regulator. Front. Physiol., 7.","DOI":"10.3389\/fphys.2016.00646"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.29076","article-title":"The Role of Sphingosine 1-phosphate Receptor 2 in Bile-acid\u2013Induced Cholangiocyte Proliferation and Cholestasis-induced Liver Injury in Mice","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e016262","DOI":"10.1161\/JAHA.119.016262","article-title":"Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Lupoli","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e149360","DOI":"10.1172\/jci.insight.149360","article-title":"Active Enterohepatic Cycling Is Not Required for the Choleretic Actions of 24-norUrsodeoxycholic Acid in Mice","volume":"8","author":"Truong","year":"2023","journal-title":"JCI Insight"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3350\/cmh.2017.0103","article-title":"NASH Therapy: Omega 3 Supplementation, Vitamin E, Insulin Sensitizers and Statin Drugs","volume":"23","author":"Caldwell","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1038\/s41467-024-48954-2","article-title":"Sphingosine D18:1 Promotes Nonalcoholic Steatohepatitis by Inhibiting Macrophage HIF-2\u03b1","volume":"15","author":"Xia","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.3748\/wjg.v29.i37.5339","article-title":"Global Trends and Hotspots of Treatment for Nonalcoholic Fatty Liver Disease: A Bibliometric and Visualization Analysis (2010\u20132023)","volume":"29","author":"Dai","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Yuan, X., Yang, L., Gao, T., Gao, J., Wang, B., Liu, C., and Yuan, W. (2024). YinChen WuLing Powder Attenuates Non-Alcoholic Steatohepatitis through the Inhibition of the SHP2\/PI3K\/NLRP3 Pathway. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1423903"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Henriksson, E., and Andersen, B. (2020). FGF19 and FGF21 for the Treatment of NASH\u2014Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.601349"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Oliviero, F., Klement, W., Mary, L., Dauwe, Y., Lippi, Y., Naylies, C., Gayrard, V., Marchi, N., and Mselli-Lakhal, L. (2023). CAR Protects Females from Diet-Induced Steatosis and Associated Metabolic Disorders. Cells, 12.","DOI":"10.3390\/cells12182218"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lee, S.S., and Schroeder, F.C. (2012). Steroids as Central Regulators of Organismal Development and Lifespan. PLoS Biol., 10.","DOI":"10.1371\/journal.pbio.1001307"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Zhai, Q., Wu, H., Zheng, S., Zhong, T., Du, C., Yuan, J., Peng, J., Cai, C., and Li, J. (2023). Association between Gut Microbiota and NAFLD\/NASH: A Bidirectional Two-Sample Mendelian Randomization Study. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1294826"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted Therapeutics and Novel Signaling Pathways in Non-Alcohol-Associated Fatty Liver\/Steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"7352","DOI":"10.3390\/ijms15057352","article-title":"Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)","volume":"15","author":"Takaki","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Liu, L., Deng, L., Wei, W., Li, C., Lu, Y., Bai, J., Li, L., Zhang, H., Jin, N., and Li, C. (2023). Lactiplantibacillus Plantarum LPJZ-658 Improves Non-Alcoholic Steatohepatitis by Modulating Bile Acid Metabolism and Gut Microbiota in Mice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813997"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic Opportunities for the Treatment of NASH with Genetically Validated Targets","volume":"79","author":"Romeo","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2302065","DOI":"10.1080\/19490976.2024.2302065","article-title":"Prophylactic Treatment with Bacteroides uniformis and Bifidobacterium bifidum Counteracts Hepatic NK Cell Immune Tolerance in Nonalcoholic Steatohepatitis Induced by High Fat Diet","volume":"16","author":"Xu","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/bjsm.2008.046151","article-title":"Review on Leptin and Adiponectin Responses and Adaptations to Acute and Chronic Exercise","volume":"44","author":"Bouassida","year":"2008","journal-title":"Br. J. Sports Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jhep.2019.12.008","article-title":"Clinical Validation of the FLIP Algorithm and the SAF Score in Patients with Non-Alcoholic Fatty Liver Disease","volume":"72","author":"Nascimbeni","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","article-title":"Future Trends in the Treatment of Non-Alcoholic Steatohepatitis","volume":"134","author":"Fiorucci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/liv.14355","article-title":"Current Management of Non-alcoholic Steatohepatitis","volume":"40","author":"Muthiah","year":"2020","journal-title":"Liver Int."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jhep.2022.06.018","article-title":"Digital Pathology with Artificial Intelligence Analyses Provides Greater Insights into Treatment-Induced Fibrosis Regression in NASH","volume":"77","author":"Naoumov","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00281-021-00869-6","article-title":"Role of Bile Acids in Inflammatory Liver Diseases","volume":"43","author":"Evangelakos","year":"2021","journal-title":"Semin. Immunopathol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/15\/3066\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:04Z","timestamp":1760033644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/15\/3066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":193,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["molecules30153066"],"URL":"https:\/\/doi.org\/10.3390\/molecules30153066","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}